At Paragon Biosciences our philosophy is simple: start with what the patient needs, understand the science behind the disease and then build companies completely focused on addressing unmet needs. That is what drives our successful model of rational drug development which helps speed the approval of important medicines. More than 6,000 diseases today that do not have a treatment available. We will make that number smaller, and help patients live longer, better lives.
We develop companies with disciplined, targeted strategies that address specific clinical areas.
Castle Creek Pharmaceuticals (CCP), part of the Paragon Biosciences portfolio of innovative biotech companies, is a privately held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions. The company has a robust and diversified pipeline of late-stage products that have the potential to transform lives. For more information, please visit www.castlecreekpharma.com.
Harmony Biosciences is a biopharmaceutical company focused on identifying, developing, obtaining regulatory approval, and commercializing high-potential, innovative drugs to address unmet needs for patients with sleep and central nervous system (CNS) disorders. For more information, please visit www.harmonybiosciences.com.
Decade is a research and development company focused on novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes and quality of life.
Precision is a research and development driven organization focused on developing complex treatments in rare genetic oncology diseases.